Bioequivalence study of a proposed biosimilar insulin glargine U300 with Toujeo®

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504509-36-00

Acronym

GARGN-IJZ-1005

Enrollment

Registered

2023-06-20

Start date

Unknown

Completion date

2024-05-30

Last updated

2023-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026